All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Lia Perez, Moffitt Cancer Center, Tampa, US. We asked, Can the combination of HDAC inhibitor panobinostat plus tacrolimus and sirolimus reduce aGVHD?
Can the combination of HDAC inhibitor panobinostat plus tacrolimus and sirolimus reduce aGVHD?
Lia Perez discusses findings of a preliminary study in which panobinostat, a histone deacetylase (HDAC) inhibitor, was tested for the ability to prevent GvHD. The maximum tolerated dose was established by the team and positive results were obtained in terms of GvHD response. Following on from these data, the group investigated a combination of panobinostat with tacrolimus and sirolimus for reducing rates of acute (a)GvHD.
Educational theme: Impact of the stem cell source on GvHD
Highlights of content that the GvHD Hub has previously published to enhance knowledge on the effect of stem cell source on GvHD risk and help clinicians make an informed decision when it comes...
Editorial theme | Considerations for allo-HSCT from mismatched unrelated donors
A mini review on the current considerations regarding HLA-mismatched related or unrelated donors allo-HSCTs.
Subscribe to get the best content related to GvHD delivered to your inbox